First Time Loading...

Zymeworks Inc
NYSE:ZYME

Watchlist Manager
Zymeworks Inc Logo
Zymeworks Inc
NYSE:ZYME
Watchlist
Price: 8.26 USD 1.85%
Updated: Apr 29, 2024
Section:
 

Wall Street
Price Targets

ZYME Price Targets Summary
Zymeworks Inc

Wall Street analysts forecast ZYME stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ZYME is 14.93 USD with a low forecast of 10.1 USD and a high forecast of 22.05 USD.

ZYME Lowest Forecast
Wall Street Target
10.1 USD
22% Upside
ZYME Average Forecast
Wall Street Target
14.93 USD
81% Upside
ZYME Highest Forecast
Wall Street Target
22.05 USD
167% Upside
Lowest
Price Target
10.1 USD
22% Upside
Average
Price Target
14.93 USD
81% Upside
Highest
Price Target
22.05 USD
167% Upside
Zymeworks Inc Competitors:
Price Targets
S
688336
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
41% Upside
DTIL
Precision BioSciences Inc
281% Upside
C
049960
Cell Biotech Co Ltd
380% Upside
NTLA
Intellia Therapeutics Inc
229% Upside
S
688336
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
41% Upside
DTIL
Precision BioSciences Inc
281% Upside
C
049960
Cell Biotech Co Ltd
380% Upside
NTLA
Intellia Therapeutics Inc
229% Upside
A
ALVO
Alvotech SA
19% Upside
RYTM
Rhythm Pharmaceuticals Inc
55% Upside
NBIX
Neurocrine Biosciences Inc
13% Upside
ENLV
Enlivex Therapeutics Ltd
308% Upside

Revenue
Forecast

Revenue Estimate
Zymeworks Inc

For the last 8 years the compound annual growth rate for Zymeworks Inc's revenue is 29%. The projected CAGR for the next 3 years is 24%.

29%
Past Growth
24%
Estimated Growth
Estimates Accuracy
40%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Zymeworks Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-11%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Zymeworks Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-35%
Average Miss
What are analyst estimates?

See Also

Summary
ZYME intrinsic value, competitors valuation, and company profile.
DCF Valuation
ZYME stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ZYME stock valuation using valuation multiples.
Wall Street Estimates
ZYME price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ZYME stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ZYME's stock price target?
Price Target
14.93 USD

According to Wall Street analysts, the average 1-year price target for ZYME is 14.93 USD with a low forecast of 10.1 USD and a high forecast of 22.05 USD.

What is Zymeworks Inc's Revenue forecast?
Projected CAGR
24%

For the last 8 years the compound annual growth rate for Zymeworks Inc's revenue is 29%. The projected CAGR for the next 3 years is 24%.

ALPHA SPREAD
Join more than 132,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.